3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
24
Stomach Neoplasms
10
Pancreatic Neoplasms
10
Rectal Neoplasms
9
Colonic Neoplasms
9
Adenocarcinoma Of Esophagus
8
Esophageal Neoplasms
7
Urinary Bladder Neoplasms
6
Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
5
Adenocarcinoma
5
Squamous Cell Carcinoma of Head and Neck
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Cholangiocarcinoma
4
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Carcinoma, Hepatocellular
3
Carcinoma
3
Ovarian Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Hepatoblastoma
2
Gallbladder Neoplasms
2
Biliary Tract Neoplasms
2
Anus Neoplasms
2
Advanced Solid Tumors
2
Uterine Cervical Neoplasms
1
Urothelial Carcinoma of the Bladder
1
Urologic Neoplasms
1
Interventions
pembrolizumab
7
Specimen Handling
6
Human Papillomavirus DNA Tests
4
Colposcopy
4
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Fulvestrant
3
Cisplatin
3
Carboplatin
3
palbociclib
2
lenvatinib
2
Surveys and Questionnaires
2
Radiation Dose Hypofractionation
2
Nivolumab
2
Magnetic Resonance Imaging
2
Gemcitabine
2
Biopsy
2
Bevacizumab
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tisotumab vedotin
1
sapanisertib
1
ribociclib
1
relatlimab
1
pertuzumab
1
patritumab deruxtecan
1
osimertinib
1
omipalisib
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Fluorouracil
×
30 days
×
Clear all
NCT06535607
2026-05-26
eVOLVE-02
AstraZeneca
Phase 2
Recruiting
257 enrolled